You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

PAMELOR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Pamelor patents expire, and what generic alternatives are available?

Pamelor is a drug marketed by Specgx Llc and is included in two NDAs.

The generic ingredient in PAMELOR is nortriptyline hydrochloride. There are twelve drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the nortriptyline hydrochloride profile page.

Drug patent expirations by year for PAMELOR
Drug Prices for PAMELOR

See drug prices for PAMELOR

Drug Sales Revenue Trends for PAMELOR

See drug sales revenues for PAMELOR

Recent Clinical Trials for PAMELOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Mental Health (NIMH)Phase 4
Centre for Addiction and Mental HealthPhase 4
National Cancer Institute (NCI)Phase 1

See all PAMELOR clinical trials

Pharmacology for PAMELOR

US Patents and Regulatory Information for PAMELOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-001 Approved Prior to Jan 1, 1982 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-003 Approved Prior to Jan 1, 1982 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-002 Approved Prior to Jan 1, 1982 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-004 Approved Prior to Jan 1, 1982 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Specgx Llc PAMELOR nortriptyline hydrochloride SOLUTION;ORAL 018012-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PAMELOR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-001 Approved Prior to Jan 1, 1982 ⤷  Try a Trial ⤷  Try a Trial
Specgx Llc PAMELOR nortriptyline hydrochloride SOLUTION;ORAL 018012-001 Approved Prior to Jan 1, 1982 ⤷  Try a Trial ⤷  Try a Trial
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-003 Approved Prior to Jan 1, 1982 ⤷  Try a Trial ⤷  Try a Trial
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-002 Approved Prior to Jan 1, 1982 ⤷  Try a Trial ⤷  Try a Trial
Specgx Llc PAMELOR nortriptyline hydrochloride CAPSULE;ORAL 018013-004 Approved Prior to Jan 1, 1982 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PAMELOR

See the table below for patents covering PAMELOR around the world.

Country Patent Number Title Estimated Expiration
Brazil 6461109 ⤷  Try a Trial
Belgium 650988 ⤷  Try a Trial
France 4407 ⤷  Try a Trial
Sweden 331992 ⤷  Try a Trial
Germany 1468341 ⤷  Try a Trial
Switzerland 494730 Verfahren zur Herstellung von Dibenzocyclopentenen (Dibenzo cycloheptenes) ⤷  Try a Trial
Netherlands 6408512 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.